-
Product Insights
NewLikelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Peanut Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Peanut Allergy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Peanut Allergy Drug Details: LOU-064 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Secondary Progressive Multiple Sclerosis (SPMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remibrutinib in Relapsing Multiple Sclerosis (RMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remibrutinib in Relapsing Multiple Sclerosis (RMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remibrutinib in Relapsing Multiple Sclerosis (RMS) Drug Details: LOU-064...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-1102 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS 107248)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Follicular Lymphoma Drug Details: Orelabrutinib (Inokai) acts as an anti-cancer...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Parkinson's Disease Drug Details: MP-101 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MP-101 in Primary Progressive Multiple Sclerosis (PPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MP-101 in Primary Progressive Multiple Sclerosis (PPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MP-101 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:...